Cochlear Ltd (ASX: COH) is one of the world’s leading medical businesses. Cochlear designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Graeme Clark invented the first device in 1982, allowing first-user Graham Carrick to hear for the first time for 17 years. Some of the most recent modifications allow users to play sound from their phone directly into their implant.
Healthcare companies around the world right now have tailwinds and competitive advantages pushing their growth. The BetaShares Global Healthcare ETF (ASX: DRUG) wants to take advantage of that.
Shares in Clinuvel Pharmaceuticals Limited (ASX:CUV) were down as much as 21% today to be one of the worst performers on the ASX 200.
If the Australian dollar continues to fall against the US dollar, I think it’s worth looking at shares of CSL Limited (ASX: CSL), Cochlear Limited (ASX: COH) and Altium Limited (ASX: ALU).
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.13% at lunch.
Cochlear Limited (ASX:COH) has released its FY19 report, is it time to buy shares?
The ASX 200 (INDEXASX:XJO)(^AXJO) is expected to open lower today, the USA’s S&P 500 Index (.INX) rose by 0.25% on Thursday.
The BetaShares Global Sustainability Leaders ETF (ASX:ETHI) and the BetaShares Australian Sustainability Leaders ETF (ASX:FAIR) are two options.
The 52-week high price for Cochlear Limited (ASX: COH) shares is $221.44. Up almost 20% in the last three months, could Cochlear reach these highs again?
The ASX 200 (INDEXASX:XJO)(^AXJO) is expected to open higher today, the USA’s S&P 500 Index (.INX) rose by 0.18% on Friday.
